Sarepta Therapeutics Inc (NASDAQ:SRPT) – Stock analysts at Leerink Swann issued their Q2 2018 earnings estimates for shares of Sarepta Therapeutics in a research report issued on Wednesday, according to Zacks Investment Research. Leerink Swann analyst J. Schwartz anticipates that the biotechnology company will earn ($0.34) per share for the quarter. Leerink Swann currently has a “Outperform” rating and a $66.00 target price on the stock. Leerink Swann also issued estimates for Sarepta Therapeutics’ Q3 2018 earnings at ($0.25) EPS and Q4 2018 earnings at ($0.19) EPS.
SRPT has been the subject of a number of other research reports. Credit Suisse Group reissued an “outperform” rating and issued a $81.00 price objective on shares of Sarepta Therapeutics in a report on Monday, October 2nd. Robert W. Baird reissued a “buy” rating and issued a $101.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, October 17th. Oppenheimer reissued a “buy” rating and issued a $76.00 price objective on shares of Sarepta Therapeutics in a report on Wednesday, December 27th. William Blair reissued an “outperform” rating on shares of Sarepta Therapeutics in a report on Monday, October 2nd. Finally, BidaskClub raised shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and eighteen have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $63.88.
Shares of Sarepta Therapeutics (NASDAQ SRPT) opened at $61.52 on Friday. The company has a market cap of $3,812.64, a PE ratio of -30.01 and a beta of 1.37. The company has a debt-to-equity ratio of 0.04, a quick ratio of 9.52 and a current ratio of 10.44. Sarepta Therapeutics has a twelve month low of $26.26 and a twelve month high of $61.89.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.86) by $0.66. The business had revenue of $45.95 million during the quarter, compared to the consensus estimate of $41.29 million. Sarepta Therapeutics had a negative net margin of 112.08% and a negative return on equity of 51.72%. During the same quarter in the previous year, the firm posted ($0.95) EPS.
Large investors have recently bought and sold shares of the company. Jennison Associates LLC boosted its stake in Sarepta Therapeutics by 103.9% during the third quarter. Jennison Associates LLC now owns 1,143,853 shares of the biotechnology company’s stock worth $51,885,000 after acquiring an additional 582,894 shares in the last quarter. Alyeska Investment Group L.P. bought a new position in shares of Sarepta Therapeutics in the third quarter valued at $26,011,000. Voya Investment Management LLC lifted its stake in shares of Sarepta Therapeutics by 2,786.1% in the second quarter. Voya Investment Management LLC now owns 568,525 shares of the biotechnology company’s stock valued at $19,165,000 after buying an additional 548,826 shares in the last quarter. Gilder Gagnon Howe & Co. LLC raised its holdings in shares of Sarepta Therapeutics by 3,599.4% in the third quarter. Gilder Gagnon Howe & Co. LLC now owns 534,087 shares of the biotechnology company’s stock valued at $24,226,000 after purchasing an additional 519,650 shares during the last quarter. Finally, HealthCor Management L.P. raised its holdings in shares of Sarepta Therapeutics by 31.1% in the second quarter. HealthCor Management L.P. now owns 2,031,890 shares of the biotechnology company’s stock valued at $68,495,000 after purchasing an additional 481,890 shares during the last quarter. 82.02% of the stock is currently owned by institutional investors.
In other Sarepta Therapeutics news, SVP Shamim Ruff sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $55.00, for a total value of $550,000.00. Following the completion of the transaction, the senior vice president now directly owns 37,045 shares in the company, valued at approximately $2,037,475. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the company’s stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $55.89, for a total transaction of $372,618.63. Following the completion of the transaction, the director now owns 13,333 shares of the company’s stock, valued at $745,181.37. The disclosure for this sale can be found here. 9.60% of the stock is owned by corporate insiders.
WARNING: “Research Analysts Offer Predictions for Sarepta Therapeutics Inc’s Q2 2018 Earnings (SRPT)” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://ledgergazette.com/2018/01/13/sarepta-therapeutics-inc-to-post-q2-2018-earnings-of-0-34-per-share-leerink-swann-forecasts-srpt.html.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.